CDChristopher Allen Droege

Christopher Allen Droege

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher Allen Droege has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safety Evaluation of Weight-Tiered, Anti-Xa-Guided Versus Fixed-Dose Enoxaparin Prophylaxis in Traumatic IntraCranial Hemorrhage (SAFE-ICH): A Retrospective Cohort Study

    by Brittany Michele Curran, Carolyn D. Philpott, Madeline Foertsch, Christopher A. Droege, Kiranpal Sangha, Lauren M. Dehne, Laura B. Ngwenya, Amy T. Makley, Molly E. Droege

    Background: Traumatic intracranial hemorrhage (tICH) increases venous thromboembolism (VTE) risk counterbalanced by a life-threatening bleed in a critical organ space. Weight-tiered and anti-Xa-guided enoxaparin dosing may reduce VTE incidence, but current literature is limited regarding safety in patients with tICH. Objective: The purpose of this study was to evaluate the progression of tICH in trauma patients on fixed-dose (FD) versus weight-tiered, anti-Xa-guided enoxaparin for VTE prophylaxis. Methods: This single-center, retrospective study included adult patients admitted to an academic, level 1 trauma center between January 2013 and October 2022. Inclusion criteria were acute tICH and ≥1 prophylactic enoxaparin dose given within 7 days of admission. Groups were FD enoxaparin 30 mg every 12 hours versus weight-tiered, anti-Xa dose-adjusted (DA) enoxaparin per institutional protocols. The primary endpoint was tICH expansion, defined as new or enlarging tICH on computed tomography (CT) or need for neurologic operative intervention within 14 days from chemoprophylaxis initiation. The secondary endpoint compared VTE incidence. A multivariate logistic regression identified risk factors for tICH expansion. Results: A total of 595 patients were included (119 FD; 476 DA). Baseline characteristics were well-matched between groups, including time from stable head CT to chemoprophylaxis initiation. The FD cohort received a lower weight-based dose compared with the DA cohort (0.40 [0.33-0.47] mg/kg/dose vs 0.45 [0.37-0.53] mg/kg/dose, P = 0.001). Traumatic ICH expansion was significantly higher in the FD cohort compared with DA (5 [4.2%] vs 5 [1.1%], P = 0.017). There were similar rates of VTE (2.5% vs 3.6%, P = 0.57) between groups. No independent risk factors were identified for progression of tICH, but higher body mass index was associated with reduced risk. Conclusion and relevance: Higher initial enoxaparin doses and anti-Xa-driven adjustment were not associated with greater rates of tICH expansion in this study, albeit an overall low incidence. These findings highlight the multifactorial nature of TBI and tICH expansion.

  • Open Access

    Multicenter Retrospective Review of Ketamine Use in Pediatric Intensive Care Units (Ketamine‐PICU Study)

    by Christine M. Groth, Christopher A. Droege, Preeyaporn Sarangarm, Michaelia D. Cucci, Kyle A. Gustafson, Kathryn A. Connor, Kimberly Kaukeinen, Nicole M. Acquisto, Sai Ho J. Chui, Deepali Dixit, et al.

    Objective. Describe continuous infusion (CI) ketamine practices in pediatric intensive care units (PICUs) and evaluate its effect on pain/sedation scores, exposure to analgesics/sedatives, and adverse effects (AEs). Methods. Multicenter, retrospective, observational study in children Results. Twenty‐four patients from 4 PICUs were included; median (IQR) age 7 (1‐13.25) years, 54% female (n = 13), 92% intubated (n = 22), 25% on CI vasopressors (n = 6), and 33% on CI paralytics (n = 8). Ketamine indications were analgesia/sedation (n = 21, 87.5%) and status epilepticus (n = 3, 12.5%). Median starting dose was 0.5 (0.48–0.70) mg/kg/hr and continued for a median of 2.4 (1.3–4.4) days. There was a significant difference in mean proportion of time spent within goal pain score range (24H prior: 74% ± 14%, 0–24H: 85% ± 10%, and 25−48H: 72% ± 20%; p = 0.014). A significant reduction in median morphine milligram equivalents (MME) was seen (24H prior: 58 (8–195) mg vs. 0–24H: 4 (0–69) mg and p = 0.01), but this was not sustained (25−48H: 24 (2–246) mg and p = 0.29). Common AEs were tachycardia (63%), hypotension (54%), secretions/suctioning (29%), and emergence reactions (13%). Conclusions. Ketamine CI improved time in goal pain score range and significantly reduced MME, but this was not sustained. Larger prospective studies are needed in the pediatric population.


  • Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury

    by Sarah Schuman Harlan, Carolyn D. Philpott, Shaun P. Keegan, Molly E. Droege, Aniruddha S. Karve, Brandon Foreman, Devin Wakefield, Eric W Mueller, Kiranpal Sangha, Laura B. Ngwenya, et al.

    Background: Drug pharmacokinetics (PK) are altered in neurocritically ill patients, and optimal levetiracetam dosing for seizure prophylaxis is unknown. Objective: This study evaluates levetiracetam PK in critically ill patients with severe traumatic brain injury (sTBI) receiving intravenous levetiracetam 1000 mg every 8 (LEV8) to 12 (LEV12) hours for seizure prophylaxis. Methods: This prospective, open-label study was conducted at a level 1 trauma, academic, quaternary care center. Patients with sTBI receiving seizure prophylaxis with LEV8 or LEV12 were eligible for enrollment. Five sequential, steady-state, postdose serum levetiracetam concentrations were obtained. Non-compartmental analysis (NCA) and compartmental approaches were employed for estimating pharmacokinetic parameters and projecting steady-state trough concentrations. Pharmacokinetic parameters were compared between LEV8 and LEV12 patients. Monte Carlo simulations (MCS) were performed to determine probability of target trough attainment (PTA) of 6 to 20 mg/L. A secondary analysis evaluated PTA for weight-tiered levetiracetam dosing. Results: Ten male patients (5 LEV8; 5 LEV12) were included. The NCA-based systemic clearance and elimination half-life were 5.3 ± 1.2 L/h and 4.8 ± 0.64 hours. A one-compartment model provided a higher steady-state trough concentration for the LEV8 group compared with the LEV12 group (13.7 ± 4.3 mg/L vs 6.3 ± 1.7 mg/L; P = 0.008). Monte Carlo simulations predicted regimens of 500 mg every 6 hours, 1000 mg every 8 hours, and 2000 mg every 12 hours achieved therapeutic target attainment. Weight-tiered dosing regimens achieved therapeutic target attainment using a 75 kg breakpoint. Conclusion and Relevance: Neurocritically ill patients exhibit rapid levetiracetam clearance resulting in a short elimination half-life. Findings of this study suggest regimens of levetiracetam 500 mg every 6 hours, 1000 mg every 8 hours, or 2000 mg every 12 hours may be required for optimal therapeutic target attainment. Patient weight of 75 kg may serve as a breakpoint for weight-guided dosing to optimize levetiracetam therapeutic target attainment for seizure prophylaxis.


  • Retrospective Evaluation of Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa for the Treatment of Traumatic Retained Hemothorax: A 6-Year Experience

    by Christopher Francis Janowak, Bradley Robert Becker, Carolyn Dosen Philpott, Amy Teres Makley, Eric William Mueller, Christopher Allen Droege, Molly Elizabeth Droege

    Background: Intrapleural fibrinolytic instillation is second-line treatment for retained hemothorax. Dornase alfa (DNase) has demonstrated efficacy in parapneumonic effusion, but the lack of deoxyribonucleoproteins limits direct extrapolation to traumatic retained hemothorax treatment. Objective: This study evaluated the effectiveness of intrapleural tissue plasminogen activator (tPA) with and without DNase in the treatment of retained traumatic hemothorax. Methods: This retrospective cohort study included patients aged 16 years and older admitted to a level 1 trauma center from January 2013 through July 2019 with retained hemothorax and one or more intrapleural tPA instillations. Exclusion criteria were tPA for other indications or concomitant empyema. The primary endpoint was treatment failure defined as the need for operative intervention. Results: Fifty patients were included (tPA alone: 28; tPA with DNase: 22). Baseline characteristics were similar between groups, including time to diagnosis (6.5 [interquartile range (IQR), 4-15.5] days vs 6 [IQR, 6.3-10.8] days, P = 0.52). Median tPA dose per treatment (6 [IQR, 6-6.4] mg vs 10 [IQR, 8.4-10] mg, P < 0.001) and cumulative tPA (18 [IQR, 6.5-24] mg vs 30 [IQR, 29.5-40], P < 0.001) dose were significantly lower in the tPA alone group. Treatment failure was similar between groups. Chest tube output, retained hemothorax reduction, and bleeding incidences were similar between groups. Multivariate logistic regression demonstrated no significant risk factors for treatment failure. Conclusions and Relevance: Dornase alfa added to tPA may not reduce the need for operation to treat retained hemothorax. Further studies should be directed at optimal tPA dose determination and economic impact of inappropriate DNase use.


  • Impact of antithrombin III and enoxaparin dosage adjustment on prophylactic anti-Xa concentrations in trauma patients at high risk for venous thromboembolism: a randomized pilot trial

    by Molly Elizabeth Droege, Christopher Allen Droege, Carolyn Dosen Philpott, Megan Leslie Webb, Neil Edward Ernst, Krishna Athota, Devin Wakefield, Joseph Richard Dowd, Dina Gomaa, Bryce H. R. Robinson, et al.

    The impact of antithrombin III activity (AT-III) on prophylactic enoxaparin anti-factor Xa concentration (anti-Xa) is unknown in high-risk trauma patients. So too is the optimal anti-Xa-adjusted enoxaparin dosage. This prospective, randomized, pilot study sought to explore the association between AT-III and anti-Xa goal attainment and to preliminarily evaluate two enoxaparin dosage adjustment strategies in patients with subprophylactic anti-Xa. Adult trauma patients with Risk Assessment Profile (RAP) ≥ 5 prescribed enoxaparin 30 mg subcutaneously every 12 h were eligible. AT-III and anti-Xa were drawn 8 h after the third enoxaparin dose and compared between patients with anti-Xa ≥ 0.1 IU/mL (goal; control group) or anti-Xa < 0.1 IU/mL (subprophylactic; intervention group). The primary outcome was difference in baseline AT-III. Subsequently, intervention group patients underwent 1:1 randomization to either enoxaparin 40 mg every 12 h (up to 50 mg every 12 h if repeat anti-Xa < 0.1 IU/mL) (enox12) or enoxaparin 30 mg every 8 h (enox8) with repeat anti-Xa assessments. The proportion of patients achieving goal anti-Xa after dosage adjustment were compared. A total of 103 patients were included. Anti-Xa was subprophylactic in 50.5%. Baseline AT-III (median [IQR]) was 87% [80–98%] in control patients versus 82% [71–96%] in intervention patients (p = 0.092). Goal trough anti-Xa was achieved on first assessment in 38.1% enox12 versus 50% enox8 patients (p = 0.67), 84.6% versus 53.3% on second assessment (p = 0.11), and 100% vs. 54.5% on third trough assessment (p = 0.045). AT-III activity did not differ between high-risk trauma patients with goal and subprophylactic enoxaparin anti-Xa concentrations, although future investigation is warranted. Enoxaparin dose adjustment rather than frequency adjustment may be associated with a higher proportion of patients achieving goal anti-Xa over time.


  • Major publications in the critical care pharmacotherapy literature: January–December 2016

    by Deanna Horner, Diana Altshuler, Chris Droege, Joel Feih, Kevin Ferguson, Mallory Fiorenza, Kasey Greathouse, Leslie Hamilton, Caitlin Pfaff, Lauren Roller, et al.


  • 616

    by Abby Rhoades, Molly Droege, Chris Droege, Megan Welch, Neil Ernst, Shaun Keegan, Eric Mueller

  • 581

    by Patrick Welch, Chris Droege, Jessica Winter, Neil Ernst, Shaun Keegan, Kiranpal Sangha, Eric Mueller

  • 439

    by Desiree Kosmisky, Chris Droege, Neil Ernst, Kristen Hillebrand, Shaun Keegan, Eric Mueller

  • 1108

    by Megan Welch, Molly Droege, Chris Droege, Neil Ernst, Shaun Keegan, Bryce Robinson, Eric Mueller